I-124 + PGN650

**I-124 + PGN650** is a combination investigational radiopharmaceutical composed of the radioisotope ^124^Iodine (I-124) conjugated to PGN650, a F(ab')2 antibody fragment that targets **phosphatidylserine** (PS), a membrane phospholipid abnormally exposed on tumor cells and vasculature under oxidative stress or after therapy. It is designed as a positron emission tomography (PET) imaging agent to act as a biomarker for the tumor microenvironment and to monitor tumor response to therapy. PGN650 is derived from human immunoglobulin IgG1 (PGN635), and binds PS with high affinity via a complex with β-2 glycoprotein 1. This conjugate allows for noninvasive imaging of apoptosis and PS exposure in tumors. Early first-in-human studies indicate the compound is safe, but PET tumor uptake was lower than observed in preclinical (animal) models. The main application is PET imaging in patients with known or suspected solid tumors as part of clinical research[1][3][5][7].

Other names

PGN650 PET imaging agentPGN-650 PET imaging agentPGN 650 PET imaging agent